Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)

Parkinson's Disease Clinical Trial

Official title:

Genetic Epidemiology of Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00104585
• Other study ID #: AAAA5609
• Secondary ID: R01NS036630
• Status: Recruiting
• Phase: N/A
• First received: March 1, 2005
• Last updated: January 18, 2012
• Start date: July 2004

Study information

• Verified date: January 2012
• Source: Columbia University
• Contact: Helen Mejia-Santana, M.A.
• Phone: 877-305-2438
• Email: research[@]corepdstudy.org
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate genetic and environmental risk factors that increase susceptibility to the development of early-onset Parkinson's disease (developed at or before age 50).

Description:

Parkinson's disease (PD) is a common, neurodegenerative condition. Although mostly a late-onset disorder, 10 percent of people with PD are reported to develop symptoms before the age of 50. To date, six genes have been found to be associated with PD, however the majority have been found in rare PD 'families'. Some studies have also identified a number of environmental risk factors, such as pesticide use, that appear to increase the risk of PD.

In a previous study, Dr. Karen Marder and her research team found that close family members of people with both early- and late-onset PD have a three-fold increased risk of PD compared to close family members of people without PD.

The purpose of the Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) study is to identify the genetic factors that contribute to the development of early-onset Parkinson's disease, and to understand how these genetic factors interact with other genes and the environment to cause PD.

Participation in the study involves a blood draw (to look for genetic factors associated with PD), questionnaires collecting information on family and medical history, and a neurological examination. In addition participants may be contacted in the future and asked to participate in a more detailed interview. At that time, study investigators will also ask participants for permission to contact family members to invite them to participate in the study.

This research study requires participants to sign a consent form, which states that the research is voluntary and confidential. In addition, since this is a research study, genetic results are not released to participants or their family members now or in the future.

Scientists hope this multi-center study will increase the current knowledge of PD and that the identification of factors that cause PD will lead to better diagnosis and treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 800
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any person with Parkinson's disease in the United States whose symptoms began at age 50 or younger and was diagnosed by a neurologist.

Study Design

Observational Model: Family-Based, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
United States	Johns Hopkins Hospital	Baltimore	Maryland
United States	Rush University Medical Center	Chicago	Illinois
United States	Glenbrook Hospital, Evanston	Glenview	Illinois
United States	Struthers Parkinson's Center	Golden Valley	Minnesota
United States	Marshfield Clinic	Marshfield	Wisconsin
United States	University of Tennessee Health Science Center	Memphis	Tennessee
United States	The Institute for Neurodegenerative Disorders	New Haven	Connecticut
United States	Beth Israel Medical Center	New York	New York
United States	Columbia University	New York	New York
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	The Parkinson's Institute	Sunnyvale	California
United States	Neuro Health	Warwick	Rhode Island

Sponsors (2)

Lead Sponsor	Collaborator
Columbia University	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States,